These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 24318486)

  • 81. Cost-efficient HIV-1 drug resistance surveillance using multiplexed high-throughput amplicon sequencing: implications for use in low- and middle-income countries.
    Ekici H; Rao SD; Sönnerborg A; Ramprasad VL; Gupta R; Neogi U
    J Antimicrob Chemother; 2014 Dec; 69(12):3349-55. PubMed ID: 25085657
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Inverse relationship between viral load and genotypic resistance mutations in Korean patients with primary HIV type 1 infections.
    Chin BS; Choi J; Nam JG; Kee MK; Suh SD; Choi JY; Chu C; Kim SS
    AIDS Res Hum Retroviruses; 2006 Nov; 22(11):1142-7. PubMed ID: 17147501
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Polymorphisms and drug resistance analysis of HIV-1 isolates from patients on first line antiretroviral therapy (ART) in South-eastern Nigeria.
    Udeze AO; Olaleye DO; Odaibo GN
    PLoS One; 2020; 15(4):e0231031. PubMed ID: 32267869
    [TBL] [Abstract][Full Text] [Related]  

  • 84. First data on HIV-1 resistance mutations to antiretroviral drugs in Central African Republic.
    Moussa S; Pinson P; Pelembi P; Gody JC; Mbitikon O; Fikouma V; Mbay P; Fleury HJ
    AIDS Res Hum Retroviruses; 2010 Nov; 26(11):1247-8. PubMed ID: 20939688
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Increasing HIV-1 pretreatment drug resistance among antiretroviral-naïve adults initiating treatment between 2006 and 2014 in Nairobi, Kenya.
    Chung MH; Silverman R; Beck IA; Yatich N; Dross S; McKernan-Mullin J; Bii S; Tapia K; Stern J; Chohan B; Sakr SR; Kiarie JN; Frenkel LM
    AIDS; 2016 Jun; 30(10):1680-2. PubMed ID: 27058353
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Resistance-associated mutation prevalence according to subtypes B and non-B of HIV type 1 in antiretroviral-experienced patients in Minas Gerais, Brazil.
    Westin MR; Biscione FM; Fonseca M; Ordones M; Rodrigues M; Greco DB; Tupinambas U
    AIDS Res Hum Retroviruses; 2011 Sep; 27(9):981-7. PubMed ID: 21361745
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Surveillance of HIV-1 primary infections in France from 2014 to 2016: toward stable resistance, but higher diversity, clustering and virulence?
    Visseaux B; Assoumou L; Mahjoub N; Grude M; Trabaud MA; Raymond S; Wirden M; Morand-Joubert L; Roussel C; Montes B; Bocket L; Fafi-Kremer S; Amiel C; De Monte A; Stefic K; Pallier C; Tumiotto C; Maillard A; Vallet S; Ferre V; Bouvier-Alias M; Dina J; Signori-Schmuck A; Carles MJ; Plantier JC; Meyer L; Descamps D; Chaix ML;
    J Antimicrob Chemother; 2020 Jan; 75(1):183-193. PubMed ID: 31641777
    [TBL] [Abstract][Full Text] [Related]  

  • 88. High discordance in blood and genital tract HIV-1 drug resistance in Indian women failing first-line therapy.
    Saravanan S; Gomathi S; Delong A; Kausalya B; Sivamalar S; Poongulali S; Brooks K; Kumarasamy N; Balakrishnan P; Solomon SS; Cu-Uvin S; Kantor R
    J Antimicrob Chemother; 2018 Aug; 73(8):2152-2161. PubMed ID: 29800305
    [TBL] [Abstract][Full Text] [Related]  

  • 89. HIV-1 integrase drug-resistance mutations in Iranian treatment-experienced HIV-1-infected patients.
    Marjani A; Bokharaei-Salim F; Jahanbakhshi F; Monavari SH; Esghaei M; Kalantari S; Kiani SJ; Ataei-Pirkooh A; Fakhim A; Keyvani H
    Arch Virol; 2020 Jan; 165(1):115-125. PubMed ID: 31741096
    [TBL] [Abstract][Full Text] [Related]  

  • 90. HIV-1 residual risk and pre-treatment drug resistance among blood donors: A sentinel surveillance from Gabon.
    Mangala C; Takou D; Maulot-Bangola D; Beloumou G; Rebienot Pellegrin O; Sosso SM; Ambe Chenwi C; Ngoufack Jagni Semengue E; Vigan Codjo F; Boussougou O; Nka AD; Tommo M; Fainguem N; Kamgaing R; Ama Moor V; Kamga Gonsu H; Penlap V; Nkoa T; Colizzi V; Perno CF; Fokam J; Ndjolo A
    PLoS One; 2024; 19(9):e0305935. PubMed ID: 39226273
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Drug resistance mutations and viral load in human immunodeficiency virus type 2 and dual HIV-1/HIV-2 infected patients in Ghana.
    Abana CZ; Sagoe KWC; Bonney EY; Maina EK; Aziati ID; Agbosu E; Mawuli G; Styer LM; Ishikawa K; Brandful JAM; Ampofo WK
    Medicine (Baltimore); 2019 Feb; 98(6):e14313. PubMed ID: 30732150
    [TBL] [Abstract][Full Text] [Related]  

  • 92. HIV-1 resistance genotyping on dried serum spots.
    Plantier JC; Dachraoui R; Lemée V; Gueudin M; Borsa-Lebas F; Caron F; Simon F
    AIDS; 2005 Mar; 19(4):391-7. PubMed ID: 15750392
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Accumulation of HIV-1 Drug Resistance Mutations After First-Line Immunological Failure to Evaluate the Options of Recycling NRTI Drugs in Second-Line Treatment: A Study from South India.
    Sivamalar S; Dinesha TR; Gomathi S; Pradeep A; Boobalan J; Solomon SS; Poongulali S; Solomon S; Balakrishnan P; Saravanan S
    AIDS Res Hum Retroviruses; 2017 Mar; 33(3):271-274. PubMed ID: 27460519
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Long-Range HIV Genotyping Using Viral RNA and Proviral DNA for Analysis of HIV Drug Resistance and HIV Clustering.
    Novitsky V; Zahralban-Steele M; McLane MF; Moyo S; van Widenfelt E; Gaseitsiwe S; Makhema J; Essex M
    J Clin Microbiol; 2015 Aug; 53(8):2581-92. PubMed ID: 26041893
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Clinical utility of genotypic resistance tests for HIV-1-infected patients with low-level virological failure.
    Elgalib A; Perry M; Aboud M; Mullen J; O'Shea S; Chrystie IL; Kulasegaram R; Tong CY
    J Clin Microbiol; 2010 Sep; 48(9):3358-9. PubMed ID: 20631106
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Comparison of genotypic resistance mutations in treatment-naive HIV type 1-infected patients in Korea and China.
    Chin BS; Choi JY; Han Y; Kuang J; Li Y; Han SH; Choi H; Chae YT; Jin SJ; Baek JH; Lim YS; Kim CO; Song YG; Yong D; Li T; Kim JM
    AIDS Res Hum Retroviruses; 2010 Feb; 26(2):217-21. PubMed ID: 20156103
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Clinical and Public Health Implications of HIV- Genetic Diversity and Drug Resistance Mutations in Angola: A Systematic Review.
    Sebastião CS; Morais J; Brito M
    AIDS Rev; 2020 Oct; 23(1):48-56. PubMed ID: 33105474
    [TBL] [Abstract][Full Text] [Related]  

  • 98. MiDRM
    Aralaguppe SG; Ambikan AT; Ashokkumar M; Kumar MM; Hanna LE; Amogne W; Sönnerborg A; Neogi U
    Viruses; 2019 Aug; 11(9):. PubMed ID: 31480341
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Shall I trust the report? Variable performance of Sanger sequencing revealed by deep sequencing on HIV drug resistance mutation detection.
    Chen NY; Kao SW; Liu ZH; Wu TS; Tsai CL; Lin HH; Wong WW; Chang YY; Chen SS; Ku SW
    Int J Infect Dis; 2020 Apr; 93():182-191. PubMed ID: 32061862
    [TBL] [Abstract][Full Text] [Related]  

  • 100. HIV-1 subtype diversity and immuno-virological outcomes among adolescents failing antiretroviral therapy in Cameroon: A cohort study.
    Togna Pabo WLR; Fokam J; Njume D; Takou D; Santoro MM; Nyasa RB; Chenwi C; Mpouel ML; Beloumou G; Jagni ESN; Nka AD; Ka'e AC; Teto G; Dambaya B; Djupsa S; Gouissi Anguechia DH; Evariste M; Kamta C; Bala L; Lambo V; Halle-Ekane EG; Colizzi V; Perno CF; Ndjolo A; Ndip Ndip R
    PLoS One; 2023; 18(10):e0293326. PubMed ID: 37878637
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.